Acromegaly Treatment Quality of Life Study
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Skin Cancer, Endocrine |
| Therapuetic Areas: | Endocrinology, Oncology |
| Healthy: | No |
| Age Range: | 18 - 75 |
| Updated: | 11/8/2017 |
| Start Date: | January 2013 |
| End Date: | August 2017 |
Effect of Growth Hormone Receptor Antagonism and Somatostatin Analog Administration on Quality of Life
The investigators hypothesize that treatment of acromegaly will be associated with an
improvement in quality of life compared to active acromegaly. At the same time, they will
also be studying the effects of different acromegaly treatments on the quality of life.
improvement in quality of life compared to active acromegaly. At the same time, they will
also be studying the effects of different acromegaly treatments on the quality of life.
Inclusion Criteria:
- Age 18-90
- Active acromegaly or receiving pegvisomant monotherapy or receiving somatostatin
analog monotherapy
Exclusion Criteria:
- Untreated thyroid or adrenal insufficiency. Subjects on replacement therapy must be
stable for at least 3 months prior to entry into the study
- Initiation or discontinuation of testosterone or estrogen within 3 months of entry
- Pregnant and nursing women
We found this trial at
1
site
185 Cambridge Street
Boston, Massachusetts 02114
Boston, Massachusetts 02114
617-724-5200
Phone: 617-724-1837
Click here to add this to my saved trials
